Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 12
HOS-126859 · Präparat HOS-096317
Diarrhoea In the pivotal trial CLEOPATRA in metastatic breast cancer, diarrhoea occurred in 68.4% of Perjeta- treated patients and 48.7% of placebo-treated patients (see section 4.4). Most events were mild to moderate in severity and occurred in the first few cycles of treatment. The incidence of NCI-CTCAE Grade 3-4 diarrhoea was 9.3% in Perjeta-treated patients vs 5.1% in placebo-treated patients. The median duration of the longest episode was 18 days in Perjeta-treated patients and 8 days in placebo- treated patients. Diarrhoeal events responded well to proactive management with anti-diarrhoeal agents.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage 7ea8d7e5b2d1583a64f8ccb905dcc747c5d4ec12de17b35354a0122c1f544292 · Zeichen 15625–16236 im Abschnitt